Sermonix Pharmaceuticals, Inc.
COLUMBUS, OH · Founded 2014 · CIK 0001655566 · Biotech · Private
Lasofoxifene, a selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer with ESR1 mutations
sermonixpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $43M
- 3 Form D · Nov 2021
- 59 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 18
- 2 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,020,000 | |
| Private capital raised | Form D · SEC | $1,550,000 | |
| Private capital raised | Form D · SEC | $40,225,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2912 | Aiolos Bio | — | — |
| 2913 | GENSAIC, INC. | — | — |
| 2914 | TRUCODE GENE REPAIR, INC. | — | — |
| 2915 | Sermonix Pharmaceuticals, Inc. | — | $43M |
| 2916 | VACCINEX, INC. | — | $44M |
| 2917 | STELLATE DNA LLC | — | — |
| 2918 | Propeller Bio | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Elizabeth AttiasExecutive Officer
- Richard De SchutterDirector
- Michael FriedmanDirector
- Elizabeth GarnerDirector
- Simon JenkinsExecutive Officer
- Barry KommExecutive Officer
- Thomas PfistererDirector
- Paul PlourdeExecutive Officer
- David PortmanDirector · Executive Officer · Promoter
- Miriam PortmanDirector · Executive Officer · Promoter
- Patrick WieselDirector
- Anthony WildDirector · Executive Officer
Patents
- Lasofoxifene Treatment Of Aromatase-resistant Er+ Cancerapplication
- Lasofoxifene Treatment Of Aromatase-resistant Er+ Cancergranted
- Lasofoxifene Treatment Of Aromatase-resistant Er+ Cancergranted
- Lasofoxifene Treatment Of Aromatase-resistant Er+ Cancerapplication
- Lasofoxifene Treatment Of Vva And Osteoporosis In Survivors Of Breast Cancer And Other Malignanciesapplication
- Lasofoxifene Treatment Of Vva And Osteoporosis In Survivors Of Breast Cancer And Other Malignanciesapplication
- Lasofoxifene Combination Treatment Of Er+ Breast Cancer That Has Progressed On A CDK4/6 Inhibitorapplication
- Lasofoxifene Combination Treatment Of Er+ Breast Cancer That Has Progressed On A CDK4/6 Inhibitorapplication
- Lasofoxifene Treatment Of Aromatase-resistant Er+ Cancerapplication
- Lasofoxifene Combination Treatment Of Er+ Breast Cancer That Has Progressed On A CDK4/6 Inhibitorapplication
- Lasofoxifene Treatment Of Vva And Osteoporosis In Survivors Of Breast Cancer And Other Malignanciesapplication
- Neoadjuvant Treatment Of Er+ Breast Cancer With Lasofoxifeneapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.